DexCom, Inc.

Day range

$77.82 – $79.51

Open

$78.68

Prev close

$78.32

Volume

5.22M

Market cap

$29.55B

Shares out

377.36M

P/E

29.56

P/S

5.95

P/B

11.27

P/FCF

21.04

ROE

38.1%

ROA

15.5%

Debt/Equity

0.47

Div yield

0.00%

As of Oct 22, 2026

• Executive leadershipSep 14, 2026

  In connection with Mr. Sylvain's promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the "Offer Letter") providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company's Amended and Restated 2015 Equity Incentive Plan, to participate in the Company's Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.

• Board of directorsSep 10, 2026

  “On September 10, 2026, the Board of Directors ... increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.” “The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation Committee and the Audit Committee of the Board, effective immediately.”

• Shareholder meetingsMay 28, 2026

  On May 27, 2026, DexCom, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting")... Dexcom stockholders elected the following twelve nominees to the Company's board of directors... Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom's independent registered public accounting firm... Dexcom stockholders approved, on a non-binding advisory basis, the compensation of Dexcom's named executive officers.

• Shareholder returnsMay 15, 2026

  On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than June 30, 2027. In connection with the approval of the Share Repurchase Program, the Board of Directors terminated its existing share repurchase program, of which $250.0 million remained available to be repurchased under the program.

• Executive leadershipMar 2, 2026

  Kevin R. Sayer notified the Board of Directors (the "Board") of DexCom, Inc. ("Dexcom" or the "Company") of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.

• PODDInsulet Corporation+0.60%
• ITGRInteger Holdings Corporation-0.02%
• ABTAbbott Laboratories+1.16%
• AMNAMN Healthcare Services+2.54%
• HQYHealthEquity, Inc+2.97%

Days to cover

3.2

Short interest

14.02M

Avg volume

4.44M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale
  positiveGlobeNewswire Inc.· Oct 21, 2026
• DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
  positiveZacks Investment Research· Oct 20, 2026
• Vaso Stock Surges 149% in a Year: What's Behind the Rally?
  positiveZacks Investment Research· Oct 16, 2026
• Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
  neutralZacks Investment Research· Oct 13, 2026
• DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
  positiveZacks Investment Research· Oct 2, 2026